UNILIFE CORPORATION (NASDAQ:UNIS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 5, 2017, David Hastings, SVP, Chief Financial Officer and Chief Accounting Officer of Unilife Corporation (the “Company”), notified the Company of his resignation from the Company, effective June 9, 2017, to pursue other opportunities. Post resignation, Mr. Hastings has agreed to serve as an advisor to the Company.
John Ryan, Unilife’s President and Chief Executive Officer, commented, “We are thankful for Dave’s leadership and many contributions to the Company, wish him well in his future endeavors and look forward to working with him in his new role as an advisor to the Company.”
About UNILIFE CORPORATION (NASDAQ:UNIS)
Unilife Corporation is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies supplying them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Its other products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a health care provider or end user without having the device pre-filled by a pharmaceutical company.
